Newswire (Published: Tuesday, May 29, 2018, Received: Friday, May 25, 2018, 1:53:28 PM CDT)

Word Count: 392

New Prostate Cancer Findings Reported from National Cancer Institute ("Super-active surveillance"MRI ultrasound fusion biopsy and ablation for less invasive management of prostate cancer)

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting from Bethesda, Maryland, by NewsRx journalists, research stated, "Multiparametric magnetic resonance imaging (mpMRI) of the prostate has allowed clinicians to better visualize and target suspicious lesions during biopsy. Targeted prostate biopsies give a more accurate representation of the true cancer volume and stage so that appropriate treatment or active surveillance can be selected."

The news correspondents obtained a quote from the research from National Cancer Institute, "Advances in technology have led to the development of MRI and ultrasound fusion platforms used for targeted biopsies, monitoring cancer progression, and more recently for the application of focal therapy. Lesions visualized on mpMRI can be targeted for ablation with a variety of energy sources employed under both local and general anesthesia. Focal ablation may offer an alternative option for treating prostate cancer as compared to the well-established interventions of whole-gland radiation or prostatectomy. Focal ablation may also be an option for patients on active surveillance who wish to be even more 'active' in their surveillance."

According to the news reporters, the research concluded: "In this review, we describe the advancements and development of fusion biopsies, the rationale behind focal therapy, and introduce focal ablative techniques for indolent prostate cancers ('super-active surveillance'), including cryoablation and focal laser ablation (FLA) and the subsequent MRI/biopsy surveillance."

For more information on this research see: "Super-active surveillance"MRI ultrasound fusion biopsy and ablation for less invasive management of prostate cancer. Gland Surgery, 2018;7(2):166-187 (see also Oncology - Prostate Cancer).

Our news journalists report that additional information may be obtained by contacting J.B. Bloom, Urologic Oncology Branch, National Cancer Institute, Bethesda, MD, United States. Additional authors for this research include S.A. Gold, G.R. Hale, K.N. Rayn, V.K. Sabarwal, I. Bakhutashvili, V. Valera, B. Turkbey, P.A. Pinto and B.J Wood.

Keywords for this news article include: Bethesda, Maryland, Oncology, Epidemiology, United States, Prostate Cancer, Health and Medicine, Prostatic Neoplasms, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

Companies

National Cancer Institute

Industries

Healthcare
      Medical Devices
            Medical Diagnostic Equipment
                  Medical Imaging Equipment
Manufacturing
      Medical Device Manufacturing
            Medical Devices
                  Medical Diagnostic Equipment
                        Medical Imaging Equipment

Places

Central America
North America
United States
Americas
Maryland
Bethesda

Subjects

Science and Technology
      Scientific Research
      Technology
            Laser Technology
            Technology Trends
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer